What changed from existing technology?
This study looked at how common fungal skin infections are in people with rheumatoid arthritis and compared them to healthy people, finding more infections in those with the disease.
This is the first study to specifically examine the association between dermatophytosis and DMARD therapy in rheumatoid arthritis patients.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
isease-modifying antirheumatic drug (DMARD) therapy in patients with rheumatoid arthritis (RA). This prospective study was conducted in a rheumatology clinic
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study suggests that dermatophytosis may be more common in RA patients, particularly those on DMARD therapy, but further research is needed to confirm this association.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.